Breaking News Instant updates and real-time market news.

LGND

Ligand

$97.32

-1.22 (-1.24%)

18:19
10/07/16
10/07
18:19
10/07/16
18:19

Ligand partner Lundbeck announces FDA approval of Carnexiv injection

Ligand Pharmaceuticals partner Lundbeck announced today that the U.S. FDA has approved Carnexiv injection as a short-term replacement therapy for oral carbamazepine formulations in adults with certain seizure types when oral administration is temporarily not feasible. Carnexiv received orphan drug designation for this indication and will be the first available intravenous formulation of the antiepileptic drug carbamazepine. Lundbeck plans to make Carnexiv commercially available in the United States in early 2017. With the approval, Ligand has earned a $1.25M milestone payment. Ligand is also entitled to receive a royalty of 2.75% on net sales of Carnexiv.

LGND Ligand
$97.32

-1.22 (-1.24%)

09/07/16
ROTH
09/07/16
NO CHANGE
Target $149
ROTH
Buy
Ligand has 'major catalyst' ahead, says Roth Capital
Roth Capital analyst Joseph Pantginis says Ligand (LGND) is expecting a "major catalyst" this month namely the Phase IIb sparsentan data in focal segmental glomerulosclerosis patients being developed by partner Retrophin (RTRX). In a separate note to investors, Pantginis also said that the Breakthrough Therapy Designation of SAGE Therapeutics' (SAGE) '547 for postpartum depression may expedite its development and approval for use in the clinic, noting that the company has an agreement of 3% royalty payment to Ligand for potential sales of the drug. The analyst recommends steady accumulation of Ligand's stock as he anticipates that current revenue streams from partnered products and the broad "in development" portfolio are poised to drive significant growth in the near and longer term. He reiterates a Buy rating and $149 price target on Ligand's shares.
09/07/16
ROTH
09/07/16
NO CHANGE
Target $151
ROTH
Buy
Ligand target raised to $151 after sparsentan data at Roth Capital
Roth Capital analyst Joseph Pantginis raised his price target for Ligand Pharmaceuticals (LGND) to $151 from $149 after the company's partner Retrophin (RTRX) announced positive data from the sparsentan Phase II study in focal segmental glomerulosclerosis patients. The analyst believes the data support a potential accelerated path forward and he reminds investors that FSGS has no approved therapies. Pantginis calls the data an important win for Ligand and Retrophin. He keeps a Buy rating on Ligand. The stock is up 7% to $115.21 in early trading.
09/07/16
09/07/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. ConocoPhillips (COP) upgraded to Hold from Underperform at Jefferies with analyst Jason Gammel citing valuation and improving financial metrics. 2. DineEquity (DIN) upgraded to Overweight from Sector Weight at KeyBanc with analyst Chris O'Cull saying the stock has reached a good entry point, while its risk/reward ratio is "compelling." 3. Gaming and Leisure Properties (GLPI) upgraded to Overweight at Morgan Stanley. 4. Aviva (AV) upgraded to Buy from Neutral at UBS with the firm saying the company is positioned to be the risk-adjusted dividend leader in the sector. 5. Ligand (LGND) upgraded to Hold from Sell at Deutsche Bank. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/05/16
HCWC
10/05/16
NO CHANGE
Target $160
HCWC
Buy
Ligand price target raised to $160 from $146 at H.C. Wainwright
H.C. Wainwright analyst Carol Ann Werther raised her price target for Ligand Pharmaceuticals to $160 citing three recent positive events, namely positive Phase II focal segmental glomerulosclerosis data from partner Retrophin, the beginning of a Phase II clinical trial with LGD-6972 for the treatment of type 2 diabetes and the licensing of several therapeutic programs to Seelos. Werther keeps a Buy rating on Ligand.

TODAY'S FREE FLY STORIES

F

Ford

$13.23

0.07 (0.53%)

08:37
01/16/18
01/16
08:37
01/16/18
08:37
Periodicals
Ford sees savings in 'every part' of business, FT reports »

Ford will have to make…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

MDXG

MiMedx

$13.86

-0.08 (-0.57%)

08:36
01/16/18
01/16
08:36
01/16/18
08:36
Hot Stocks
MiMedx: First patients enrolled in Phase 3 clinical trial of AmnioFix Injectable »

MiMedx Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

UCTT

Ultra Clean

$23.22

0.47 (2.07%)

08:36
01/16/18
01/16
08:36
01/16/18
08:36
Hot Stocks
Ultra Clean sees Q1 revenue up from Q4 »

The company said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

LBCC

Long Blockchain Corp.

$5.02

-0.48 (-8.73%)

08:35
01/16/18
01/16
08:35
01/16/18
08:35
Hot Stocks
Breaking Hot Stocks news story on Long Blockchain Corp. »

Long Blockchain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRAY

Cray

08:35
01/16/18
01/16
08:35
01/16/18
08:35
Earnings
Cray sees FY17 revenue about $390M, consensus $399.96M »

Cray announced selected…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

LNG

Cheniere Energy

$54.73

0.29 (0.53%)

08:34
01/16/18
01/16
08:34
01/16/18
08:34
Hot Stocks
Cheniere Energy, Trafigura sign 15-year LNG sale and purchase agreement »

Cheniere Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

UCTT

Ultra Clean

$23.22

0.47 (2.07%)

08:34
01/16/18
01/16
08:34
01/16/18
08:34
Earnings
Ultra Clean reaffirms Q4 revenue view $240.0M-$250M, consensus $244.32M »

Sees Q4 operating margins…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

PX

Praxair

$164.15

0.34 (0.21%)

08:34
01/16/18
01/16
08:34
01/16/18
08:34
Hot Stocks
Praxair expands hydrogen supply to Motiva Port Arthur, Texas refinery »

Praxair, Inc. has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

CNCE

Concert Pharmaceuticals

$20.15

-7.53 (-27.20%)

, INCY

Incyte

$94.07

1.01 (1.09%)

08:33
01/16/18
01/16
08:33
01/16/18
08:33
Downgrade
Concert Pharmaceuticals, Incyte rating change  »

Concert Pharmaceuticals…

CNCE

Concert Pharmaceuticals

$20.15

-7.53 (-27.20%)

INCY

Incyte

$94.07

1.01 (1.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

MGM

MGM Resorts

$35.03

-0.08 (-0.23%)

, LVS

Las Vegas Sands

$71.02

0.39 (0.55%)

08:33
01/16/18
01/16
08:33
01/16/18
08:33
Recommendations
MGM Resorts, Las Vegas Sands, Wynn Resorts, Melco Resorts & Entertainment analyst commentary  »

Morgan Stanley raises…

MGM

MGM Resorts

$35.03

-0.08 (-0.23%)

LVS

Las Vegas Sands

$71.02

0.39 (0.55%)

WYNN

Wynn Resorts

$165.54

3.04 (1.87%)

MLCO

Melco Resorts & Entertainment

$27.01

-0.21 (-0.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRWD

Ironwood

$15.12

0.02 (0.13%)

, AGN

Allergan

$176.05

-1.07 (-0.60%)

08:33
01/16/18
01/16
08:33
01/16/18
08:33
Hot Stocks
Ironwood, Allergan announce settlement with Sun Pharma over LINZESS »

Ironwood Pharmaceuticals…

IRWD

Ironwood

$15.12

0.02 (0.13%)

AGN

Allergan

$176.05

-1.07 (-0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

  • 16

    Feb

  • 25

    Mar

YUMC

Yum China

$45.86

2.06 (4.70%)

08:32
01/16/18
01/16
08:32
01/16/18
08:32
Hot Stocks
Yum China sees one-time tax expense of approximately $160M in Q4 »

Yum China Holdings is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

IO

ION Geophysical

$21.35

-2.7 (-11.23%)

08:32
01/16/18
01/16
08:32
01/16/18
08:32
Hot Stocks
ION Geophysical announces Supreme Court granted certiorari »

ION Geophysical announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSIS

OSI Systems

$67.68

0.19 (0.28%)

08:31
01/16/18
01/16
08:31
01/16/18
08:31
Hot Stocks
OSI Systems signs 2-year contract to continue turnkey screening services »

OSI Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jun

HRTX

Heron Therapeutics

$21.40

-0.25 (-1.15%)

, TSRO

Tesaro

$69.59

-2.07 (-2.89%)

08:31
01/16/18
01/16
08:31
01/16/18
08:31
Recommendations
Heron Therapeutics, Tesaro analyst commentary  »

Tesaro update could drive…

HRTX

Heron Therapeutics

$21.40

-0.25 (-1.15%)

TSRO

Tesaro

$69.59

-2.07 (-2.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:31
01/16/18
01/16
08:31
01/16/18
08:31
General news
Empire State Mfg Survey General Business Conditions Index data reported »

January Empire State Mfg…

LMOS

Lumos Networks

08:30
01/16/18
01/16
08:30
01/16/18
08:30
Hot Stocks
Lumos signs multi-year contract with Roanoke Blacksburg Regional Airport »

Lumos Networks signed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WP

Worldpay

$77.60

1.94 (2.56%)

, BOBE

Bob Evans

08:30
01/16/18
01/16
08:30
01/16/18
08:30
Options
One new option listing and three option delistings on January 16th »

New option listings for…

WP

Worldpay

$77.60

1.94 (2.56%)

BOBE

Bob Evans

SYT

Syngenta

VNTV

Vantiv

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAWK

Blackhawk

$36.50

-0.5 (-1.35%)

08:30
01/16/18
01/16
08:30
01/16/18
08:30
Hot Stocks
Breaking Hot Stocks news story on Blackhawk 

Blackhawk trading resumes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$257.03

1.9 (0.74%)

08:30
01/16/18
01/16
08:30
01/16/18
08:30
Hot Stocks
Marcus by Goldman Sachs now offering home improvement loans »

Marcus by Goldman Sachs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 31

    Jan

EIGR

Eiger BioPharmaceuticals

$16.00

0.65 (4.23%)

08:30
01/16/18
01/16
08:30
01/16/18
08:30
Hot Stocks
Breaking Hot Stocks news story on Eiger BioPharmaceuticals »

Eiger BioPharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Feb

  • 26

    Feb

  • 08

    Apr

GE

General Electric

$18.76

-0.26 (-1.37%)

08:29
01/16/18
01/16
08:29
01/16/18
08:29
Earnings
GE sees 2017 industrial operating & Verticals EPS at low end of $1.05-$1.10 »

Says "no…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

HTGM

HTG Molecular

$3.64

-0.07 (-1.89%)

, QGEN

Qiagen

$32.65

0.46 (1.43%)

08:28
01/16/18
01/16
08:28
01/16/18
08:28
Hot Stocks
HTG announces third statement of work for new clinical assay development program »

HTG Molecular Diagnostics…

HTGM

HTG Molecular

$3.64

-0.07 (-1.89%)

QGEN

Qiagen

$32.65

0.46 (1.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDHL

RedHill Biopharma

$5.17

-0.03 (-0.58%)

08:28
01/16/18
01/16
08:28
01/16/18
08:28
Hot Stocks
RedHill Biopharma's Phase II study of Bekinda met primary endpoint »

RedHill Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

DERM

Dermira

$27.44

0.74 (2.77%)

08:28
01/16/18
01/16
08:28
01/16/18
08:28
Recommendations
Dermira analyst commentary  »

Dermira should rally on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.